Previous 10 | Next 10 |
Anticipate topline 16-week data for all three cohorts from the Phase 1b trial for pan-BD BET inhibitor, VYN201, in nonsegmental vitiligo in the third quarter of 2023 IND-enabling studies for VYN202, a potential best-in-class oral small molecule BD2-selective BET inhibitor, are ongoing in ...
2023-05-01 11:40:49 ET VYNE Therapeutics ( NASDAQ: VYNE ) has selected a lead candidate for its oral BD2-selective bromodomain and extra-terminal inhibitor program, VYN202, used to treat immuno-inflammatory conditions. VYNE exclusively licensed the BD2-selective BET inhibitors...
Preclinical studies suggest VYN202 has the potential to be the most potent and selective BET inhibitor in development VYN202 has demonstrated a potent anti-inflammatory and anti-fibrotic effect in multiple validated preclinical models of autoimmune disease IND-enabling studies a...
2023-04-20 08:22:47 ET Windtree Therapeutics ( WINT ) -40% . Genius Group Limited ( GNS ) -12% . Nokia Oyj ( NOK ) -9% . on mixed Q1 earnings . Tesla ( TSLA ) -8% . after Q1 earning release . F5 ( FFIV ) -7% . after Q2 earn...
2023-04-19 12:49:23 ET Gainers: SAI.TECH Global Corporation ( SAI ) +48% . Bed Bath & Beyond ( BBBY ) +40% . VYNE Therapeutics ( VYNE ) +34% . Boqii Holding Limited ( BQ ) +30% . CXApp ( CXAI ) +19% . Western Alliance Ban...
VYNE Therapeutics Inc. (NASDAQ: VYNE) is one today's most active stocks by volume. So far today, approximately 29.8M shares of VYNE Therapeutics Inc. have been exchanged, as compared to an average 30-day volume of 20,405 shares. VYNE Therapeutics Inc., a pharmaceutical company, focuses on deve...
2023-04-19 10:32:41 ET If you’re looking for penny stocks to buy now, there’s a lot to account for in the stock market today. Whether it’s the overarching recession and inflation story or the underpinnings of a potential stock market crash in 2023, emotions are ridi...
2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...
2023-04-19 08:51:50 ET Vyne Therapeutics ( NASDAQ: VYNE ) stock rose ~10% premarket on Wednesday after the company said preclinical data showed positive effect of inhaled formulation of VYN201 in a mouse model of idiopathic pulmonary fibrosis (IPF). IPF is a condition in whi...
VYN201 at the 0.5 mg/ml and 1 mg/ml doses demonstrated statistically significant reductions in lung fibrosis and hydroxyproline levels compared to placebo Reduction in lung fibrosis from VYN201 treatment resulted in significant improvements in blood oxygen saturation and functional lung v...
News, Short Squeeze, Breakout and More Instantly...
VYNE Therapeutics Inc Com Company Name:
VYNE Stock Symbol:
NASDAQ Market:
VYNE Therapeutics Inc Com Website:
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory con...
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory co...